Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533719 | 0.88 | HMGCR (0.42) | TSHRALDH1A1HMGCRSMN1; SMN2 | |
| SCHEMBL5166947 | 0.84 | — | — | |
| SCHEMBL8893382 | 0.84 | HMGCR (0.33) | TSHRHMGCR | |
| SCHEMBL6852096 | 0.82 | — | — | |
| SCHEMBL10540472 | 0.81 | HMGCR (0.49) | TSHRHMGCR | |
| SCHEMBL3030008 | 0.81 | HMGCR (0.49) | TSHRHMGCR | |
| SCHEMBL28437823 | 0.81 | HMGCR (0.49) | TSHRHMGCR | |
| SCHEMBL16781660 | 0.81 | HMGCR (0.35) | HMGCR | |
| SCHEMBL29084243 | 0.78 | — | — | |
| SCHEMBL8806187 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018209239-A1 | POTENT AGELASTATIN DERIVATIVES AS MODULATORS FOR CANCER INVASION AND METASTASIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-11-15 | — | — | WO | disclosed |
| EP-2817013-A2 | ANTIMICROBIAL COMPOSITIONS, THE PREPARATION AND USE THEREOF | KCI Licensing Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013126550-A2 | NEW COMPOSITIONS, THE PREPARATION AND USE THEREOF | KCI LICENSING, INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | TSHR 2296/4885ALDH1A1 2141/4885HMGCR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.